2017年全球重症监护病房感染患病率与结局
该研究为2017年9月13日08:00起24小时内、88个国家1150个中心的观察性24小时点患病率研究并纵向随访至2017年11月13日,纳入全部成人ICU患者。15 202例患者中感染数据可获取15 165例(99.8%),8135例(54%)存在疑似或确诊感染,其中1760例(22%)为ICU获得性感染;10 640例(70%)接受了至少1种抗生素。疑似或确诊感染患者院内死亡率为30%(2404/7936)。多水平分析显示ICU获得性感染较社区获得性感染死亡风险更高(OR 1.32,95%CI 1.10-1.60;P=.003),耐万古霉素肠球菌、对β-内酰胺类(含第三代头孢菌素及碳青霉烯类)耐药的克雷伯菌、耐碳青霉烯类不动杆菌属感染亦与死亡风险升高独立相关。
要点
- 全球ICU成人患者中疑似或确诊感染占54%(8135/15165),其中ICU获得性感染占22%(1760例),抗生素暴露高达70%(10640例)。
- 疑似或确诊感染患者院内死亡率为30%(2404/7936);ICU获得性感染较社区获得性感染死亡风险更高(OR 1.32,95%CI 1.10-1.60;P=.003)。
- 感染患者中65%(5259例)至少1次微生物培养阳性,其中革兰阴性菌67%(3540例)、革兰阳性菌37%(1946例)、真菌16%(864例)。
- 耐万古霉素肠球菌感染(OR 2.41,95%CI 1.43-4.06;P=.001)、对β-内酰胺类(含第三代头孢菌素及碳青霉烯类)耐药的克雷伯菌感染(OR 1.29,95%CI 1.02-1.63;P=.03)、耐碳青霉烯类不动杆菌属感染(OR 1.40,95%CI 1.08-1.81;P=.01)均与死亡风险升高独立相关。
- 疑似或确诊感染比例地区差异明显,从澳大拉西亚的43%(141/328)到亚洲与中东的60%(1892/3150)。
适用人群与场景
- 2017年9月13日08:00起24小时期间在88个国家1150个参与中心ICU接受治疗的成人患者(年龄≥18岁)。
研究设计与关键结果
- 研究类型:观察性24小时点患病率研究并纵向随访,共纳入1150个中心、88个国家、15 202例成人ICU患者(平均年龄61.1岁,SD 17.3岁;男性9181例,60.4%),感染数据可获取15 165例(99.8%),最终随访日期为2017年11月13日。
- 主要终点(横断面):疑似或确诊感染8135例(54%),其中ICU获得性感染1760例(22%);接受至少1种抗生素10 640例(70%);疑似或确诊感染比例从澳大拉西亚43%(141/328)到亚洲与中东60%(1892/3150)。
- 病原学:感染患者中5259例(65%)至少1次微生物培养阳性,革兰阴性菌67%(3540例)、革兰阳性菌37%(1946例)、真菌16%(864例)。
- 纵向终点:疑似或确诊感染患者院内死亡率30%(2404/7936);多水平分析中ICU获得性感染较社区获得性感染死亡风险更高(OR 1.32,95%CI 1.10-1.60;P=.003)。
- 耐药菌:耐万古霉素肠球菌感染(OR 2.41,95%CI 1.43-4.06;P=.001)、对β-内酰胺类(含第三代头孢菌素及碳青霉烯类)耐药的克雷伯菌感染(OR 1.29,95%CI 1.02-1.63;P=.03)、耐碳青霉烯类不动杆菌属感染(OR 1.40,95%CI 1.08-1.81;P=.01)较其他微生物感染死亡风险更高。
证据类型、等级与局限
- 证据类型:观察性24小时点患病率研究并纵向随访。
- 局限:原文未报告局限性
对床旁实践的改变
- 该全球点患病率数据提示ICU中疑似或确诊感染常见(54%)、抗生素暴露普遍(70%),且ICU获得性感染与耐药菌感染(耐万古霉素肠球菌、对β-内酰胺类耐药的克雷伯菌、耐碳青霉烯类不动杆菌属)与院内死亡风险升高独立相关,可供ICU感染防控、诊断与治疗策略及资源分配参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Infection is frequent among patients in the intensive care unit (ICU). Contemporary information about the types of infections, causative pathogens, and outcomes can aid the development of policies for prevention, diagnosis, treatment, and resource allocation and may assist in the design of interventional studies.
OBJECTIVE: To provide information about the prevalence and outcomes of infection and the available resources in ICUs worldwide.
DESIGN, SETTING, AND PARTICIPANTS: Observational 24-hour point prevalence study with longitudinal follow-up at 1150 centers in 88 countries. All adult patients (aged ≥18 years) treated at a participating ICU during a 24-hour period commencing at 08:00 on September 13, 2017, were included. The final follow-up date was November 13, 2017.
EXPOSURES: Infection diagnosis and receipt of antibiotics.
MAIN OUTCOMES AND MEASURES: Prevalence of infection and antibiotic exposure (cross-sectional design) and all-cause in-hospital mortality (longitudinal design).
RESULTS: Among 15 202 included patients (mean age, 61.1 years [SD, 17.3 years]; 9181 were men [60.4%]), infection data were available for 15 165 (99.8%); 8135 (54%) had suspected or proven infection, including 1760 (22%) with ICU-acquired infection. A total of 10 640 patients (70%) received at least 1 antibiotic. The proportion of patients with suspected or proven infection ranged from 43% (141/328) in Australasia to 60% (1892/3150) in Asia and the Middle East. Among the 8135 patients with suspected or proven infection, 5259 (65%) had at least 1 positive microbiological culture; gram-negative microorganisms were identified in 67% of these patients (n = 3540), gram-positive microorganisms in 37% (n = 1946), and fungal microorganisms in 16% (n = 864). The in-hospital mortality rate was 30% (2404/7936) in patients with suspected or proven infection. In a multilevel analysis, ICU-acquired infection was independently associated with higher risk of mortality compared with community-acquired infection (odds ratio [OR], 1.32 [95% CI, 1.10-1.60]; P = .003). Among antibiotic-resistant microorganisms, infection with vancomycin-resistant Enterococcus (OR, 2.41 [95% CI, 1.43-4.06]; P = .001), Klebsiella resistant to β-lactam antibiotics, including third-generation cephalosporins and carbapenems (OR, 1.29 [95% CI, 1.02-1.63]; P = .03), or carbapenem-resistant Acinetobacter species (OR, 1.40 [95% CI, 1.08-1.81]; P = .01) was independently associated with a higher risk of death vs infection with another microorganism.
CONCLUSIONS AND RELEVANCE: In a worldwide sample of patients admitted to ICUs in September 2017, the prevalence of suspected or proven infection was high, with a substantial risk of in-hospital mortality.
参考来源
- Vincent JL, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA. 2020. PMID: 32207816. doi:10.1001/jama.2020.2717
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。